Bestat Welcomes Pharmapace Founders to Taiwan for Strategic Collaboration Talks
On December 10, 2025, Pharmapace, Inc. founders—CEO Larry Shen, Ph.D., and Chief Development Officer Adrian Hsing—traveled from San Diego, USA, to visit Bestat Pharmaservices Corp. The two parties engaged in in-depth discussions exploring opportunities for long-term strategic collaboration.
Pharmapace, a well-recognized U.S. CRO, has extensive hands-on experience in global drug development. During this visit, both teams held an extended meeting focusing on potential cooperation in biostatistics, data management, and related operational frameworks. The shared goal is to establish a stable, long-term partnership that strengthens cross-border clinical research capabilities.
For Bestat, this exchange signifies not only international partners’ recognition of our statistical and data management strengths, but also highlights the growing importance of Taiwan’s CRO sector within the global R&D ecosystem. Both parties expressed a common vision: to jointly enhance the efficiency, quality, and innovation of clinical trials.
This collaboration effort aligns with the United Nations Sustainable Development Goals (SDGs):
SDG 9: Industry, Innovation and Infrastructure – Advancing innovation in clinical trial technologies, data quality, and analytical methodologies through international cooperation.
SDG 17: Partnerships for the Goals – Strengthening global partnerships to support sustainable development in the biopharmaceutical industry.
Bestat will continue to expand its global collaboration network, integrate international expertise, and support partners in accelerating the development of new therapeutics—ultimately bringing better medical possibilities to patients worldwide.
On December 10, 2025, Pharmapace, Inc. founders—CEO Larry Shen, Ph.D., and Chief Development Officer Adrian Hsing—traveled from San Diego, USA, to visit Bestat Pharmaservices Corp. The two parties engaged in in-depth discussions exploring opportunities for long-term strategic collaboration.
Pharmapace, a well-recognized U.S. CRO, has extensive hands-on experience in global drug development. During this visit, both teams held an extended meeting focusing on potential cooperation in biostatistics, data management, and related operational frameworks. The shared goal is to establish a stable, long-term partnership that strengthens cross-border clinical research capabilities.
For Bestat, this exchange signifies not only international partners’ recognition of our statistical and data management strengths, but also highlights the growing importance of Taiwan’s CRO sector within the global R&D ecosystem. Both parties expressed a common vision: to jointly enhance the efficiency, quality, and innovation of clinical trials.
This collaboration effort aligns with the United Nations Sustainable Development Goals (SDGs):
SDG 9: Industry, Innovation and Infrastructure – Advancing innovation in clinical trial technologies, data quality, and analytical methodologies through international cooperation.
SDG 17: Partnerships for the Goals – Strengthening global partnerships to support sustainable development in the biopharmaceutical industry.
Bestat will continue to expand its global collaboration network, integrate international expertise, and support partners in accelerating the development of new therapeutics—ultimately bringing better medical possibilities to patients worldwide.